MK-8242 Is Active in Patients with p53 Wild-Type Advanced Solid Tumors.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2017-047
Abstract: The MDM2 inhibitor MK-8242 is tolerable in patients with liposarcoma and other advanced solid tumors. read more here.
Keywords: solid tumors; advanced solid; p53 wild; active patients ... See more keywords